Allogene Therapeutics' Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class Status
Portfolio Pulse from Vandana Singh
Allogene Therapeutics presented updated data from Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A for large B-cell lymphoma treatment, showing promising results. Analysts from William Blair and Canaccord Genuity see potential for first-in-class status and continued efficacy improvement.
June 16, 2023 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allogene Therapeutics' ALLO-501/501A shows promising results in LBCL treatment, with analysts predicting first-in-class status and continued efficacy improvement.
The updated data from the Phase 1 trials of ALLO-501/501A show promising results in treating large B-cell lymphoma. Analysts from William Blair and Canaccord Genuity predict first-in-class status and continued efficacy improvement for the therapy. This positive outlook on the company's product is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100